WCM Investment Management LLC Acquires 48,543 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

WCM Investment Management LLC lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 52.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 140,847 shares of the company's stock after purchasing an additional 48,543 shares during the quarter. WCM Investment Management LLC owned about 0.13% of Vaxcyte worth $15,935,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in Vaxcyte by 68.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 21,466 shares of the company's stock worth $2,453,000 after acquiring an additional 8,685 shares during the period. Harbor Capital Advisors Inc. lifted its stake in shares of Vaxcyte by 392.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 40,342 shares of the company's stock valued at $3,046,000 after purchasing an additional 32,149 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Vaxcyte by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company's stock worth $216,966,000 after acquiring an additional 498,359 shares in the last quarter. Swiss National Bank lifted its stake in shares of Vaxcyte by 20.4% during the first quarter. Swiss National Bank now owns 178,000 shares of the company's stock worth $12,159,000 after purchasing an additional 30,100 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Vaxcyte in the 1st quarter worth approximately $1,288,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total value of $927,520.00. Following the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at approximately $10,479,005.02. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares in the company, valued at approximately $37,822,574.24. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 117,464 shares of company stock worth $12,640,276 over the last three months. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $4.26 during mid-day trading on Tuesday, hitting $99.38. The stock had a trading volume of 1,547,424 shares, compared to its average volume of 844,264. The company has a market cap of $12.39 billion, a PE ratio of -22.53 and a beta of 1.01. Vaxcyte, Inc. has a 12-month low of $46.16 and a 12-month high of $121.06. The company's 50 day moving average is $112.01 and its 200-day moving average is $87.92.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.27. During the same quarter last year, the business posted ($0.91) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on PCVX shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Leerink Partners upped their price target on Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. BTIG Research boosted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Bank of America lifted their target price on Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research note on Wednesday, September 4th. Finally, Jefferies Financial Group boosted their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.